Ionis Pharmaceuticals Faces Investigation After Sales Guidance Cut by 50%
Ionis Pharmaceuticals Faces Scrutiny After Major Cut in Sales Forecast
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has recently become the focus of an investor investigation following a drastic reduction in its sales guidance for the TRYNGOLZA product. On November 9, 2026, the company disclosed that it had slashed its full-year sales projection by approximately 50%, estimating revenues to be around $50 million, a stark contrast to the previous range of $100 million to $110 million announced just a few months prior.
This significant drop in expectations has not only raised eyebrows within the financial community but has also led to a considerable decline in IONS' stock price. The investigation, spearheaded by the law firm Levi & Korsinsky, seeks to determine whether Ionis made materially false or misleading statements pertaining to its sales guidance that influenced investors’ decisions during the critical period leading up to the recent disclosure.
In July 2026, Ionis was optimistic about its financial outlook, claiming that TRYNGOLZA was
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.